Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis Vaccines
With
GlaxoSmithKline
Age
3–5
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Children eligible to be enrolled in the study are those whose parents provide written informed consent, and are in generally good health based on the clinical judgment of the investigators.
Group 1 and 2 (Follow up) subjects must be 40 +/- 3 months of age at the time of enrollment and participated in the original V59P14 study (NCT00474526).
Group 3 and 4 (Naïve) subjects must be healthy, meningococcal vaccine-naïve children ages 40 +/- 3 months (Group 3) or 60 +/-3 months (Group 4) at the time of enrollment, respectively.
You may not be if
Serious, acute, or chronic illnesses are reasons for exclusion.
Subjects who have received any vaccine (excluding influenza vaccines) 28 days preceding enrollment visit. Influenza vaccines (including FluMist®) are excluded for the 14 days prior to the enrollment visit.
Subjects who have received any meningococcal vaccine since birth (Groups 3 \& 4 -naive) or last study dose in V59P14 (NCT00474526) trial (Groups 1 \& 2 - follow on).
Clareo Health | Evaluation of Meningococcal Immune Response Among Children Who Previously Received MenACWY Conjugate Vaccine
